The Acute Leukaemias:@0.703132:0.035749:0.914567:0.035749:0.914567:0.019993:0.703132:0.019993:0.008197:0.011738:0.012508:0.005330:0.014239:0.012450:0.011699:0.006523:0.012508:0.005330:0.008890:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.007466
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
79:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
uncontrolled proliferation of the malignant :@0.084242:0.096166:0.480490:0.096166:0.480490:0.080410:0.084242:0.080410:0.011699:0.011738:0.012450:0.012604:0.011738:0.006523:0.005698:0.012604:0.003848:0.003848:0.012508:0.013181:0.004195:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.004181:0.012604:0.006042:0.004185:0.006523:0.011738:0.012508:0.004185:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.005330
blasts may result in extreme  leucocytosis :@0.084242:0.112609:0.480484:0.112609:0.480484:0.096854:0.084242:0.096854:0.013123:0.003848:0.013143:0.007466:0.006523:0.007466:0.008736:0.018049:0.013143:0.010314:0.008736:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.008736:0.003848:0.011738:0.008736:0.012508:0.009236:0.006523:0.005709:0.012508:0.018049:0.012508:0.005330:0.003396:0.003848:0.012508:0.011699:0.012450:0.012604:0.012450:0.010314:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330
and leukostasis with blood hyperviscos-:@0.084242:0.129053:0.475152:0.129053:0.475152:0.113297:0.084242:0.113297:0.013143:0.011738:0.013181:0.012200:0.003848:0.012508:0.011699:0.009660:0.012604:0.007466:0.006523:0.013143:0.007466:0.003848:0.007466:0.012200:0.015990:0.003848:0.006523:0.011738:0.012200:0.013123:0.003848:0.012604:0.012604:0.013181:0.012200:0.011738:0.010314:0.013123:0.012508:0.005792:0.010660:0.003848:0.007466:0.012450:0.012604:0.007466:0.006388
ity, leading to respiratory failure, uraemia :@0.084242:0.145497:0.480494:0.145497:0.480494:0.129741:0.084242:0.129741:0.003848:0.006523:0.010314:0.005330:0.007485:0.003848:0.012508:0.013143:0.013181:0.003848:0.011738:0.012950:0.007485:0.006523:0.012604:0.007476:0.005713:0.012508:0.007466:0.013123:0.003848:0.005792:0.013143:0.006523:0.012604:0.005792:0.010314:0.007485:0.006042:0.013143:0.003848:0.003848:0.011699:0.005719:0.012508:0.005330:0.007485:0.011699:0.005792:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330
and  neurological  deficit.  Therefore  the :@0.084242:0.161941:0.480503:0.161941:0.480503:0.146185:0.084242:0.146185:0.013143:0.011738:0.013181:0.005330:0.008276:0.011738:0.012508:0.011699:0.005711:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005330:0.008280:0.013181:0.012508:0.004686:0.004686:0.012450:0.003848:0.006523:0.005330:0.005330:0.008268:0.008197:0.011738:0.012508:0.005711:0.012508:0.006042:0.012604:0.005705:0.012508:0.005330:0.008272:0.006523:0.011738:0.012508:0.005330
diagnosis and  management  of  AML  is a :@0.084242:0.178385:0.480488:0.178385:0.480488:0.162629:0.084242:0.162629:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.008736:0.013143:0.011738:0.013181:0.005330:0.003394:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.005330:0.003383:0.012604:0.006042:0.005330:0.003389:0.014239:0.017684:0.008890:0.005330:0.003387:0.003848:0.007466:0.008736:0.013143:0.005330
medical emergency that will require rapid :@0.084242:0.194829:0.480470:0.194829:0.480470:0.179073:0.084242:0.179073:0.018049:0.012508:0.013181:0.003848:0.012450:0.013143:0.003848:0.005080:0.012508:0.018049:0.012508:0.005792:0.012950:0.012508:0.011738:0.012450:0.010314:0.005080:0.006523:0.011738:0.013143:0.006523:0.005070:0.015990:0.003848:0.003848:0.003848:0.005080:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.005080:0.005792:0.013143:0.013123:0.003848:0.013181:0.005330
detection and correction of these abnor-:@0.084242:0.211273:0.475175:0.211273:0.475175:0.195517:0.084242:0.195517:0.013181:0.012508:0.006523:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.006510:0.013143:0.011738:0.013181:0.006523:0.012450:0.012604:0.005792:0.005703:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.006514:0.012604:0.006042:0.006523:0.006523:0.011738:0.012508:0.007466:0.012508:0.006523:0.013143:0.013123:0.011738:0.012604:0.005792:0.006388
malities.  Depending on risk factors of the :@0.084242:0.227716:0.480499:0.227712:0.480499:0.211956:0.084242:0.211960:0.018049:0.013143:0.003848:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330:0.006226:0.006619:0.014316:0.012508:0.013123:0.012508:0.011738:0.013181:0.003848:0.011738:0.012950:0.006619:0.012604:0.011738:0.006608:0.005792:0.003848:0.007466:0.009660:0.006619:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.006608:0.012604:0.006042:0.006610:0.006523:0.011738:0.012508:0.671076
2:@0.158816:0.222093:0.165031:0.222093:0.165031:0.212907:0.158816:0.212907:0.006215
blood disorder, the patient performance :@0.084234:0.244156:0.480487:0.244156:0.480487:0.228400:0.084234:0.228400:0.013123:0.003848:0.012604:0.012604:0.013181:0.008659:0.013181:0.003848:0.007466:0.012604:0.005677:0.013181:0.012508:0.003768:0.005330:0.008659:0.006523:0.011738:0.012508:0.008659:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.008659:0.013123:0.012508:0.006706:0.006042:0.012604:0.006319:0.018049:0.013143:0.011738:0.012450:0.012508:0.005330
status and presence of comorbidities, AML :@0.084234:0.260600:0.480480:0.260600:0.480480:0.244844:0.084234:0.244844:0.007466:0.006523:0.013143:0.006523:0.011699:0.007466:0.004281:0.013143:0.011738:0.013181:0.004280:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.004274:0.012604:0.006042:0.004274:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330:0.004276:0.014239:0.017684:0.008890:0.005330
can be cured with standard combination :@0.084234:0.277044:0.480491:0.277044:0.480491:0.261288:0.084234:0.261288:0.012450:0.013143:0.011738:0.006119:0.013123:0.012508:0.006119:0.012450:0.011699:0.005711:0.012508:0.013181:0.006119:0.015990:0.003848:0.006523:0.011738:0.006119:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005678:0.013181:0.006119:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
chemotherapy  or  may  require  other  ap-:@0.084234:0.293487:0.475138:0.293487:0.475138:0.277731:0.084234:0.277731:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.003379:0.012604:0.005792:0.005330:0.003385:0.018049:0.013143:0.010314:0.005330:0.003396:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.005330:0.003392:0.012604:0.006523:0.011738:0.012508:0.005792:0.005330:0.003377:0.013143:0.013123:0.006388
proaches  such as allogeneic stem-cell :@0.084234:0.309931:0.480483:0.309931:0.480483:0.294175:0.084234:0.294175:0.013123:0.005715:0.012604:0.013143:0.012450:0.011738:0.012508:0.007466:0.005330:0.008457:0.007466:0.011699:0.012450:0.011738:0.013797:0.013143:0.007466:0.013797:0.013143:0.003848:0.003848:0.012604:0.012950:0.012508:0.011738:0.012508:0.003848:0.012450:0.013797:0.007466:0.006523:0.012508:0.018049:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330
transplantation.:@0.084234:0.326375:0.230457:0.326375:0.230457:0.310619:0.084234:0.310619:0.006523:0.005792:0.013143:0.011738:0.007466:0.013123:0.003848:0.013143:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
The  World  Health  Organization  (WHO) :@0.102418:0.342819:0.480468:0.342819:0.480468:0.327063:0.102418:0.327063:0.008197:0.011738:0.012508:0.005330:0.005559:0.017589:0.012604:0.005792:0.003848:0.013181:0.005330:0.005569:0.013143:0.012508:0.013143:0.003848:0.006523:0.011738:0.005330:0.005569:0.016722:0.005809:0.012950:0.013143:0.011738:0.003848:0.008178:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005561:0.007100:0.018473:0.013143:0.016722:0.007100:0.005330
classification of malignancies divides hae-:@0.084234:0.359263:0.475151:0.359263:0.475151:0.343507:0.084234:0.343507:0.012450:0.003848:0.013143:0.007466:0.007466:0.003848:0.004686:0.004686:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005294:0.012604:0.006042:0.005286:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.003848:0.012508:0.007466:0.005294:0.013181:0.003848:0.010660:0.003848:0.013181:0.012508:0.007466:0.005301:0.011738:0.013143:0.012508:0.006388
matological malignancies according to :@0.084234:0.375707:0.480485:0.375707:0.480485:0.359951:0.084234:0.359951:0.018049:0.013143:0.006523:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.012007:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.003848:0.012508:0.007466:0.012007:0.013143:0.012450:0.012450:0.012604:0.005669:0.013181:0.003848:0.011738:0.012950:0.012007:0.006523:0.012604:0.005330
morphology,  immunophenotyping and :@0.084234:0.392151:0.480468:0.392151:0.480468:0.376395:0.084234:0.376395:0.018049:0.012604:0.005792:0.013123:0.011738:0.012604:0.003848:0.012604:0.012950:0.010314:0.005330:0.005330:0.013516:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.013123:0.011738:0.012508:0.011738:0.012590:0.006523:0.010314:0.013123:0.003848:0.011738:0.012950:0.018858:0.013143:0.011738:0.013181:0.005330
cytogenetic/molecula  derangements :@0.084234:0.408594:0.480503:0.408594:0.480503:0.392838:0.084234:0.392838:0.013412:0.011276:0.007485:0.013566:0.013912:0.013470:0.012700:0.013470:0.007485:0.004811:0.013412:0.009371:0.019011:0.013566:0.004811:0.013470:0.013412:0.012662:0.004811:0.014105:0.005330:0.006702:0.014143:0.013470:0.006754:0.014105:0.012700:0.013912:0.013470:0.019011:0.013470:0.012700:0.007485:0.007470:0.005330
into  distinct groupings.   While the  de-:@0.084234:0.425038:0.475159:0.425032:0.475159:0.409276:0.084234:0.409282:0.003848:0.011738:0.006523:0.012604:0.005330:0.007545:0.013181:0.003848:0.007466:0.006523:0.003848:0.011738:0.012450:0.006523:0.012892:0.012950:0.005709:0.012604:0.011699:0.013123:0.003848:0.011738:0.012950:0.007466:0.005330:0.015538:0.005330:0.007551:0.018473:0.011738:0.003848:0.003848:0.012508:0.012892:0.006523:0.011738:0.012508:0.005330:0.007545:0.013181:0.012508:0.390464
3,4:@0.307710:0.419412:0.323247:0.419412:0.323247:0.410227:0.307710:0.410227:0.006215:0.003107:0.006215
tailed pathogenesis of AML is not known, :@0.084240:0.441475:0.480488:0.441475:0.480488:0.425720:0.084240:0.425720:0.006523:0.013143:0.003848:0.003848:0.012508:0.013181:0.007274:0.013123:0.013143:0.006523:0.011738:0.012604:0.012950:0.012508:0.011738:0.012508:0.007466:0.003848:0.007466:0.007256:0.012604:0.006042:0.007256:0.014239:0.017684:0.008890:0.007254:0.003848:0.007466:0.007260:0.011738:0.012604:0.006523:0.007252:0.009660:0.011738:0.012604:0.015990:0.011738:0.005330:0.005330
genomic instability due to genetic factors :@0.084240:0.457919:0.480480:0.457919:0.480480:0.442163:0.084240:0.442163:0.012950:0.012508:0.011738:0.012604:0.018049:0.003848:0.012450:0.005890:0.003848:0.011738:0.007466:0.006523:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.005907:0.013181:0.011699:0.012508:0.005896:0.006523:0.012604:0.005892:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.005894:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.005330
(Fanconi anaemia, ataxia telangiectasia), :@0.084240:0.474363:0.480461:0.474363:0.480461:0.458607:0.084240:0.458607:0.007100:0.009333:0.013143:0.011738:0.012450:0.012604:0.011738:0.003848:0.004310:0.013143:0.011738:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.004310:0.013143:0.006523:0.013143:0.009236:0.003848:0.013143:0.004310:0.006523:0.012508:0.003848:0.013143:0.011738:0.012950:0.003848:0.012508:0.012450:0.006523:0.013143:0.007466:0.003848:0.013143:0.007100:0.005330:0.005330
environmental toxins (radiation, benzene) :@0.084240:0.490807:0.480482:0.490807:0.480482:0.475051:0.084240:0.475051:0.012508:0.011738:0.010660:0.003848:0.005715:0.012604:0.011738:0.018049:0.012508:0.011738:0.006523:0.013143:0.003848:0.006406:0.006523:0.012604:0.009236:0.003848:0.011738:0.007466:0.006412:0.007100:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006408:0.013123:0.012508:0.011738:0.008178:0.012508:0.011738:0.012508:0.007100:0.005330
or cytotoxic drugs (alkylators, topoisomer-:@0.084240:0.507251:0.475150:0.507251:0.475150:0.491495:0.084240:0.491495:0.012604:0.005792:0.006146:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.006158:0.013181:0.005792:0.011699:0.012950:0.007466:0.006158:0.007100:0.013143:0.003848:0.009660:0.010314:0.003848:0.013143:0.006523:0.012604:0.005792:0.007466:0.005330:0.006158:0.006523:0.012604:0.013123:0.012604:0.003848:0.007466:0.012604:0.018049:0.012508:0.005765:0.006388
ase II inhibitors) has been  implicated. :@0.084240:0.523695:0.480488:0.523695:0.480488:0.507939:0.084240:0.507939:0.013143:0.007466:0.012508:0.014682:0.004349:0.004349:0.014682:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.007100:0.014682:0.011738:0.013143:0.007466:0.014682:0.013123:0.012508:0.012508:0.011738:0.005330:0.009340:0.003848:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330:0.005330
These factors lead to loss of genetic ma-:@0.084240:0.540139:0.475150:0.540139:0.475150:0.524383:0.084240:0.524383:0.008197:0.011738:0.012508:0.007466:0.012508:0.007505:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.007466:0.007505:0.003848:0.012508:0.013143:0.013181:0.007505:0.006523:0.012604:0.007505:0.003848:0.012604:0.007466:0.007466:0.007505:0.012604:0.006042:0.007505:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.007505:0.018049:0.013143:0.006388
terial,  point  mutations  or  chromosomal :@0.084240:0.556582:0.480480:0.556582:0.480480:0.540827:0.084240:0.540827:0.006523:0.012508:0.005792:0.003848:0.013143:0.003848:0.005330:0.005330:0.008130:0.013123:0.012604:0.003848:0.011738:0.006523:0.005330:0.008126:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.008128:0.012604:0.005792:0.005330:0.008122:0.012450:0.011738:0.005709:0.012604:0.018049:0.012604:0.007466:0.012604:0.018049:0.013143:0.003848:0.005330
translocations that cause cellular gain of :@0.084240:0.573026:0.480461:0.573026:0.480461:0.557270:0.084240:0.557270:0.006523:0.005792:0.013143:0.011738:0.007466:0.003848:0.012604:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.007870:0.006523:0.011738:0.013143:0.006523:0.007870:0.012450:0.013143:0.011699:0.007466:0.012508:0.007870:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.007870:0.012950:0.013143:0.003848:0.011738:0.007870:0.012604:0.006042:0.005330
proliferative  function  and  clonal  expan-:@0.084240:0.589470:0.475152:0.589470:0.475152:0.573714:0.084240:0.573714:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330:0.005242:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.005232:0.013143:0.011738:0.013181:0.005330:0.005240:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.005244:0.012508:0.009236:0.013123:0.013143:0.011738:0.006388
sion  of  the  malignancy.  Identification  of :@0.084240:0.605914:0.480484:0.605914:0.480484:0.590158:0.084240:0.590158:0.007466:0.003848:0.012604:0.011738:0.005330:0.004439:0.012604:0.006042:0.005330:0.004432:0.006523:0.011738:0.012508:0.005330:0.004432:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.010314:0.005330:0.005330:0.004437:0.004349:0.013181:0.012508:0.011738:0.006523:0.003848:0.004686:0.004686:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.004432:0.012604:0.006042:0.005330
these aberrant mutations, as well as epi-:@0.084240:0.622358:0.475144:0.622358:0.475144:0.606602:0.084240:0.606602:0.006523:0.011738:0.012508:0.007466:0.012508:0.008028:0.013143:0.013123:0.012508:0.005792:0.005792:0.013143:0.011738:0.006523:0.008022:0.018049:0.011699:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.008026:0.013143:0.007466:0.008034:0.015990:0.012508:0.003848:0.003848:0.008043:0.013143:0.007466:0.008043:0.012508:0.013123:0.003848:0.006388
genetic changes in malignant cells, have :@0.084240:0.638802:0.480480:0.638802:0.480480:0.623046:0.084240:0.623046:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.006465:0.012450:0.011738:0.013143:0.011738:0.012950:0.012508:0.007466:0.006465:0.003848:0.011738:0.006465:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.006465:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.006465:0.011738:0.013143:0.010660:0.012508:0.005330
resulted in better understanding of the dis-:@0.084240:0.655246:0.475148:0.655246:0.475148:0.639490:0.084240:0.639490:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.012508:0.013181:0.004849:0.003848:0.011738:0.004849:0.013123:0.012508:0.006523:0.006523:0.012508:0.005792:0.004849:0.011699:0.011738:0.013181:0.012508:0.005792:0.007466:0.006523:0.013143:0.011738:0.013181:0.003848:0.011738:0.012950:0.004849:0.012604:0.006042:0.004849:0.006523:0.011738:0.012508:0.004849:0.013181:0.003848:0.007466:0.006388
ease process and hold promise for the de-:@0.084240:0.671689:0.475157:0.671689:0.475157:0.655934:0.084240:0.655934:0.012508:0.013143:0.007466:0.012508:0.004849:0.013123:0.005715:0.012604:0.012450:0.012508:0.007466:0.007466:0.004849:0.013143:0.011738:0.013181:0.004849:0.011738:0.012604:0.003848:0.013181:0.004849:0.013123:0.005715:0.012604:0.018049:0.003848:0.007466:0.012508:0.004849:0.006042:0.012604:0.005792:0.004838:0.006523:0.011738:0.012508:0.004849:0.013181:0.012508:0.006388
velopment of specific therapies that may :@0.084240:0.688133:0.480478:0.688133:0.480478:0.672377:0.084240:0.672377:0.010660:0.012508:0.003848:0.012604:0.013123:0.018049:0.012508:0.011738:0.006523:0.006679:0.012604:0.006042:0.006677:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.006683:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.007466:0.006689:0.006523:0.011738:0.013143:0.006523:0.006675:0.018049:0.013143:0.010314:0.005330
correct these abnormalities.:@0.084240:0.704577:0.345150:0.704577:0.345150:0.688821:0.084240:0.688821:0.012450:0.012604:0.005792:0.005703:0.012508:0.012450:0.006523:0.005330:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330:0.013143:0.013123:0.011738:0.012604:0.006306:0.018049:0.013143:0.003848:0.003848:0.006523:0.003848:0.012508:0.007466:0.005330
CLINICAL PRESENTATION:@0.084242:0.737778:0.333111:0.737778:0.333111:0.719962:0.084242:0.719962:0.016677:0.009407:0.005987:0.015822:0.005987:0.016677:0.015822:0.009407:0.005987:0.011973:0.012401:0.011118:0.011118:0.011118:0.015822:0.008980:0.015822:0.008980:0.005987:0.017960:0.015822
Patients  may present  with symptoms of :@0.084242:0.755367:0.480497:0.755367:0.480497:0.739612:0.084242:0.739612:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005934:0.018049:0.013143:0.010314:0.011276:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.005330:0.005934:0.015990:0.003848:0.006523:0.011738:0.011276:0.007466:0.010314:0.018049:0.013123:0.006523:0.012604:0.018049:0.007466:0.011276:0.012604:0.006042:0.005330
marrow failure (anaemia, thrombocy-:@0.084242:0.771811:0.475144:0.771811:0.475144:0.756055:0.084242:0.756055:0.018049:0.013143:0.005792:0.005711:0.012604:0.015990:0.018434:0.006042:0.013143:0.003848:0.003848:0.011699:0.005719:0.012508:0.018434:0.007100:0.013143:0.011738:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.018434:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.012450:0.010314:0.006388
topaenia), respiratory compromise from :@0.084242:0.788255:0.480476:0.788255:0.480476:0.772499:0.084242:0.772499:0.006523:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.007100:0.005330:0.012065:0.005713:0.012508:0.007466:0.013123:0.003848:0.005792:0.013143:0.006523:0.012604:0.005792:0.010314:0.012065:0.012450:0.012604:0.018049:0.013123:0.005713:0.012604:0.018049:0.003848:0.007466:0.012508:0.012065:0.006042:0.005713:0.012604:0.018049:0.005330
malignant pleural effusions or multilobar :@0.084242:0.804699:0.480497:0.804699:0.480497:0.788943:0.084242:0.788943:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.010410:0.013123:0.003848:0.012508:0.011699:0.005792:0.013143:0.003848:0.010410:0.012508:0.006096:0.006042:0.011699:0.007466:0.003848:0.012604:0.011738:0.007466:0.010410:0.012604:0.005792:0.010410:0.018049:0.011699:0.003848:0.006523:0.003848:0.003848:0.012604:0.013123:0.013143:0.005792:0.005330
pneumonia  and  sepsis due  to  immuno-:@0.084242:0.821143:0.475152:0.821143:0.475152:0.805387:0.084242:0.805387:0.013123:0.011738:0.012508:0.011699:0.018049:0.012604:0.011738:0.003848:0.013143:0.005330:0.005392:0.013143:0.011738:0.013181:0.005330:0.005396:0.007466:0.012508:0.013123:0.007466:0.003848:0.007466:0.010737:0.013181:0.011699:0.012508:0.005330:0.005394:0.006523:0.012604:0.005330:0.005390:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006388
suppression. Metabolic derangements :@0.084242:0.837587:0.480486:0.837587:0.480486:0.821831:0.084242:0.821831:0.007466:0.011699:0.013123:0.013123:0.005719:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.022494:0.017684:0.012508:0.006523:0.013143:0.013123:0.012604:0.003848:0.003848:0.012450:0.022494:0.013181:0.012508:0.005792:0.013143:0.011738:0.012950:0.012508:0.018049:0.012508:0.011738:0.006523:0.007466:0.005330
are common, particularly in patients with :@0.084242:0.854031:0.480484:0.854031:0.480484:0.838275:0.084242:0.838275:0.013143:0.005715:0.012508:0.007331:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005330:0.007314:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.003848:0.010314:0.007331:0.003848:0.011738:0.007331:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007331:0.015990:0.003848:0.006523:0.011738:0.005330
advanced disease. Hyperuricaemia may :@0.084242:0.870474:0.480482:0.870474:0.480482:0.854718:0.084242:0.854718:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.008197:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.008197:0.013143:0.010314:0.013123:0.012508:0.005792:0.011699:0.005792:0.003848:0.012450:0.013143:0.012508:0.018049:0.003848:0.013143:0.008197:0.018049:0.013143:0.010314:0.005330
result in renal failure due to interstitial ne-:@0.084242:0.886918:0.475152:0.886918:0.475152:0.871162:0.084242:0.871162:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007293:0.003848:0.011738:0.007293:0.005711:0.012508:0.011738:0.013143:0.003848:0.007293:0.006042:0.013143:0.003848:0.003848:0.011699:0.005721:0.012508:0.007293:0.013181:0.011699:0.012508:0.007293:0.006523:0.012604:0.007293:0.003848:0.011738:0.006523:0.012508:0.005792:0.007466:0.006523:0.003848:0.006523:0.003848:0.013143:0.003848:0.007293:0.011738:0.012508:0.006388
phritis, while hyperphosphataemia, lac-:@0.084242:0.903362:0.475152:0.903362:0.475152:0.887606:0.084242:0.887606:0.013123:0.011738:0.005792:0.003848:0.006523:0.003848:0.007466:0.005330:0.013508:0.015990:0.011738:0.003848:0.003848:0.012508:0.013508:0.011738:0.010314:0.013123:0.012508:0.005792:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.013143:0.006523:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.013508:0.003848:0.013143:0.012450:0.006388
tic acidosis  and hyperkalaemia must all :@0.084242:0.919806:0.480474:0.919806:0.480474:0.904050:0.084242:0.904050:0.006523:0.003848:0.012450:0.010122:0.013143:0.012450:0.003848:0.013181:0.012604:0.007466:0.003848:0.007466:0.005330:0.004803:0.013143:0.011738:0.013181:0.010122:0.011738:0.010314:0.013123:0.012508:0.005792:0.009660:0.013143:0.003848:0.013143:0.012508:0.018049:0.003848:0.013143:0.010122:0.018049:0.011699:0.007466:0.006523:0.010122:0.013143:0.003848:0.003848:0.005330
be  actively  identified  and  corrected.  In :@0.084242:0.936250:0.480474:0.936250:0.480474:0.920494:0.084242:0.920494:0.013123:0.012508:0.005330:0.005086:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.005330:0.005093:0.003848:0.013181:0.012508:0.011738:0.006523:0.003848:0.004686:0.004686:0.012508:0.013181:0.005330:0.005080:0.013143:0.011738:0.013181:0.005330:0.005086:0.012450:0.012604:0.005792:0.005703:0.012508:0.012450:0.006523:0.012508:0.013181:0.005330:0.005330:0.005078:0.004349:0.011738:0.005330
addition, patients often have a bleeding :@0.523643:0.096171:0.919884:0.096171:0.919884:0.080415:0.523643:0.080415:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330:0.007666:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007666:0.012604:0.006042:0.006523:0.012508:0.011738:0.007655:0.011738:0.013143:0.010660:0.012508:0.007668:0.013143:0.007678:0.013123:0.003848:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.005330
tendency due to thrombocytopaenia and :@0.523643:0.112615:0.919890:0.112615:0.919890:0.096859:0.523643:0.096859:0.006523:0.012508:0.011738:0.013181:0.012508:0.011738:0.012450:0.010314:0.003904:0.013181:0.011699:0.012508:0.003912:0.006523:0.012604:0.003910:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.012450:0.010314:0.006523:0.012592:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.003925:0.013143:0.011738:0.013181:0.005330
thrombosis from disseminated intravascu-:@0.523643:0.129059:0.914523:0.129059:0.914523:0.113303:0.523643:0.113303:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.007466:0.003848:0.007466:0.007678:0.006042:0.005713:0.012604:0.018049:0.007678:0.013181:0.003848:0.007466:0.007466:0.012508:0.018049:0.003848:0.011738:0.013143:0.006523:0.012508:0.013181:0.007678:0.003848:0.011738:0.006523:0.005792:0.013143:0.010660:0.013143:0.007466:0.012450:0.011699:0.006388
lar coagulation (DIC) precipitated by the :@0.523643:0.145503:0.919875:0.145503:0.919875:0.129747:0.523643:0.129747:0.003848:0.013143:0.005792:0.006870:0.012450:0.012604:0.013143:0.012950:0.011699:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.006870:0.007100:0.014316:0.004349:0.015644:0.007100:0.006881:0.013123:0.005715:0.012508:0.012450:0.003848:0.013123:0.003848:0.006523:0.013143:0.006523:0.012508:0.013181:0.006870:0.013123:0.010314:0.006870:0.006523:0.011738:0.012508:0.005330
release of prothrombotic substances from :@0.523643:0.161947:0.919884:0.161947:0.919884:0.146191:0.523643:0.146191:0.005713:0.012508:0.003848:0.012508:0.013143:0.007466:0.012508:0.006004:0.012604:0.006042:0.005990:0.013123:0.005715:0.012604:0.006523:0.011728:0.005711:0.012604:0.018049:0.013123:0.012604:0.006523:0.003848:0.012450:0.005990:0.007466:0.011699:0.013123:0.007466:0.006523:0.013143:0.011738:0.012450:0.012508:0.007466:0.005992:0.006042:0.005713:0.012604:0.018049:0.005330
degrading blasts. This is particularly severe :@0.523643:0.178391:0.919880:0.178391:0.919880:0.162635:0.523643:0.162635:0.013181:0.012508:0.012950:0.005792:0.013143:0.013181:0.003848:0.011738:0.012950:0.005446:0.013123:0.003848:0.013143:0.007478:0.006523:0.007466:0.005330:0.005446:0.008197:0.011738:0.003848:0.007466:0.005446:0.003848:0.007466:0.005457:0.013123:0.013143:0.005792:0.006523:0.003848:0.012450:0.011699:0.003848:0.013143:0.005792:0.003848:0.010314:0.005457:0.007466:0.012508:0.010660:0.012508:0.005717:0.012508:0.005330
in the group named acute promyelocytic :@0.523643:0.194834:0.919892:0.194834:0.919892:0.179079:0.523643:0.179079:0.003848:0.011738:0.005840:0.006523:0.011738:0.012508:0.005836:0.012950:0.005713:0.012604:0.011699:0.013123:0.005834:0.011738:0.013143:0.018049:0.012508:0.013181:0.005838:0.013143:0.012450:0.011699:0.006523:0.012508:0.005834:0.013123:0.005715:0.012604:0.018049:0.010314:0.012508:0.003848:0.012604:0.012450:0.010314:0.006523:0.003848:0.012450:0.005330
leukaemia (APL). Occasionally, paraspinal :@0.523643:0.211278:0.919878:0.211278:0.919878:0.195522:0.523643:0.195522:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.004387:0.007100:0.014239:0.011392:0.008890:0.007100:0.005330:0.004387:0.016722:0.012450:0.012450:0.013143:0.007466:0.003848:0.012604:0.011738:0.013143:0.003848:0.003848:0.010329:0.005330:0.004387:0.013123:0.013143:0.005792:0.013143:0.007466:0.013123:0.003848:0.011738:0.013143:0.003848:0.005330
or other tumour masses (chloromas) may :@0.523643:0.227722:0.919877:0.227722:0.919877:0.211966:0.523643:0.211966:0.012604:0.005792:0.007508:0.012604:0.006523:0.011738:0.012508:0.005792:0.007501:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007503:0.018049:0.013143:0.007466:0.007466:0.012508:0.007466:0.007524:0.007100:0.012450:0.011738:0.003848:0.012604:0.005711:0.012604:0.018049:0.013143:0.007466:0.007100:0.007524:0.018049:0.013143:0.010314:0.005330
lead to spinal cord compression and par-:@0.523643:0.244166:0.914548:0.244166:0.914548:0.228410:0.523643:0.228410:0.003848:0.012508:0.013143:0.013181:0.006331:0.006523:0.012604:0.006315:0.007466:0.013123:0.003848:0.011738:0.013143:0.003848:0.006331:0.012450:0.012604:0.005671:0.013181:0.006331:0.012450:0.012604:0.018049:0.013123:0.005709:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.006315:0.013143:0.011738:0.013181:0.006331:0.013123:0.013143:0.005792:0.006388
aplegia. Central nervous system (CNS) in-:@0.523643:0.260610:0.914552:0.260610:0.914552:0.244854:0.523643:0.244854:0.013143:0.013123:0.003848:0.012508:0.012950:0.003848:0.013143:0.005330:0.006677:0.015644:0.012508:0.011738:0.006523:0.005792:0.013143:0.003848:0.006677:0.011738:0.012508:0.005792:0.010660:0.012604:0.011699:0.007466:0.006677:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.006677:0.007100:0.015644:0.014239:0.009583:0.007100:0.006677:0.003848:0.011738:0.006388
filtration by myelogenous leukaemia is not :@0.523643:0.277054:0.919892:0.277054:0.919892:0.261298:0.523643:0.261298:0.004686:0.004686:0.003848:0.006523:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005434:0.013123:0.010314:0.005449:0.018049:0.010314:0.012508:0.003848:0.012604:0.012950:0.012508:0.011738:0.012604:0.011699:0.007466:0.005434:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.005451:0.003848:0.007466:0.005449:0.011738:0.012604:0.006523:0.005330
common  on presentation,  but patients :@0.523643:0.293498:0.919880:0.293498:0.919880:0.277742:0.523643:0.277742:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005330:0.007687:0.012604:0.011738:0.013027:0.013123:0.005713:0.012508:0.007466:0.012508:0.011738:0.006523:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.007687:0.013123:0.011699:0.006523:0.013027:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
may develop focal signs due to intracra-:@0.523643:0.309941:0.914562:0.309941:0.914562:0.294185:0.523643:0.294185:0.018049:0.013143:0.010314:0.007351:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.007351:0.006042:0.012604:0.012450:0.013143:0.003848:0.007351:0.007466:0.003848:0.012950:0.011738:0.007466:0.007351:0.013181:0.011699:0.012508:0.007351:0.006523:0.012604:0.007341:0.003848:0.011738:0.006523:0.005792:0.013143:0.012450:0.005792:0.013143:0.006388
nial bleeding or thrombosis.:@0.523643:0.326385:0.778762:0.326385:0.778762:0.310629:0.523643:0.310629:0.011738:0.003848:0.013143:0.003848:0.005330:0.013123:0.003848:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.005330:0.012604:0.005792:0.005330:0.006523:0.011738:0.005700:0.012604:0.018049:0.013123:0.012604:0.007466:0.003848:0.007466:0.005330
2:@0.778757:0.320753:0.784972:0.320753:0.784972:0.311567:0.778757:0.311567:0.006215
DIAGNOSIS:@0.523636:0.359582:0.640373:0.359582:0.640373:0.341767:0.523636:0.341767:0.014966:0.005987:0.015822:0.017960:0.015822:0.017960:0.011118:0.005987:0.011118
The diagnosis  requires a detailed history :@0.523636:0.377172:0.919866:0.377172:0.919866:0.361416:0.523636:0.361416:0.008197:0.011738:0.012508:0.009891:0.013181:0.003848:0.013143:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.005330:0.004572:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.007466:0.009891:0.013143:0.009891:0.013181:0.012508:0.006523:0.013143:0.003848:0.003848:0.012508:0.013181:0.009891:0.011738:0.003848:0.007466:0.006523:0.012604:0.005792:0.010314:0.005330
and thorough physical examination to :@0.523636:0.393615:0.919895:0.393615:0.919895:0.377860:0.523636:0.377860:0.013143:0.011738:0.013181:0.013970:0.006523:0.011738:0.012604:0.005707:0.012604:0.011699:0.012950:0.011726:0.013970:0.013123:0.011738:0.010314:0.007466:0.003848:0.012450:0.013143:0.003848:0.013970:0.012508:0.009236:0.013143:0.018049:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.013970:0.006523:0.012604:0.005330
determine pre-existence of genetic pre-:@0.523636:0.410059:0.914572:0.410059:0.914572:0.394303:0.523636:0.394303:0.013181:0.012508:0.006523:0.012508:0.006317:0.018049:0.003848:0.011738:0.012508:0.009583:0.013123:0.005715:0.012508:0.006388:0.012508:0.009236:0.003848:0.007466:0.006523:0.012508:0.011738:0.012450:0.012508:0.009583:0.012604:0.006042:0.009583:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.009583:0.013123:0.005717:0.012508:0.006388
disposition, previous exposure to  noxious :@0.523636:0.426503:0.919897:0.426503:0.919897:0.410747:0.523636:0.410747:0.013181:0.003848:0.007466:0.013123:0.012604:0.007466:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330:0.009640:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.009640:0.012508:0.009236:0.013123:0.012604:0.007466:0.011699:0.005711:0.012508:0.009640:0.006523:0.012604:0.005330:0.004297:0.011738:0.012604:0.009236:0.003848:0.012604:0.011699:0.007466:0.005330
agents and presence of infection, bleed-:@0.523636:0.442947:0.914545:0.442947:0.914545:0.427191:0.523636:0.427191:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.006735:0.013143:0.011738:0.013181:0.006735:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.012450:0.012508:0.006735:0.012604:0.006042:0.006735:0.003848:0.011738:0.006042:0.012508:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.006735:0.013123:0.003848:0.012508:0.012508:0.013181:0.006388
ing or masses  that may compromise the :@0.523636:0.459391:0.919887:0.459391:0.919887:0.443635:0.523636:0.443635:0.003848:0.011738:0.012950:0.008544:0.012604:0.005792:0.008544:0.018049:0.013143:0.007466:0.007466:0.012508:0.007466:0.005330:0.003225:0.006523:0.011738:0.013143:0.006523:0.008544:0.018049:0.013143:0.010314:0.008544:0.012450:0.012604:0.018049:0.013123:0.005715:0.012604:0.018049:0.003848:0.007466:0.012508:0.008544:0.006523:0.011738:0.012508:0.005330
function of vital organs. The current clas-:@0.523636:0.475835:0.914538:0.475835:0.914538:0.460079:0.523636:0.460079:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.007726:0.012604:0.006042:0.007735:0.010660:0.003848:0.006523:0.013143:0.003848:0.007735:0.012604:0.005804:0.012950:0.013143:0.011738:0.007466:0.005330:0.007735:0.008197:0.011738:0.012508:0.007735:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.006523:0.007735:0.012450:0.003848:0.013143:0.007466:0.006388
sification  of  AML  was  developed  under :@0.523636:0.492279:0.919891:0.492279:0.919891:0.476523:0.523636:0.476523:0.007466:0.003848:0.004686:0.004686:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005636:0.012604:0.006042:0.005330:0.005632:0.014239:0.017684:0.008890:0.005330:0.005634:0.015990:0.013143:0.007466:0.005330:0.005644:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.012508:0.013181:0.005330:0.005640:0.011699:0.011738:0.013181:0.012508:0.005792:0.005330
the auspices of the World Health Organi-:@0.523636:0.508722:0.914549:0.508722:0.914549:0.492966:0.523636:0.492966:0.006523:0.011738:0.012508:0.007412:0.013143:0.011699:0.007466:0.013123:0.003848:0.012450:0.012508:0.007466:0.007428:0.012604:0.006042:0.007418:0.006523:0.011738:0.012508:0.007414:0.017588:0.012604:0.005792:0.003848:0.013181:0.007416:0.013143:0.012508:0.013143:0.003848:0.006523:0.011738:0.007428:0.016722:0.005807:0.012950:0.013143:0.011738:0.003848:0.006388
zation (WHO) which incorporates clinical :@0.523636:0.525166:0.919843:0.525166:0.919843:0.509410:0.523636:0.509410:0.008178:0.013143:0.006523:0.003848:0.012604:0.011738:0.008447:0.007100:0.018473:0.013143:0.016722:0.007100:0.008447:0.015990:0.011738:0.003848:0.012450:0.011738:0.008447:0.003848:0.011738:0.012450:0.012604:0.005792:0.013123:0.012604:0.005778:0.013143:0.006523:0.012508:0.007466:0.008447:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.005330
features in combination with laboratory :@0.523636:0.541610:0.919906:0.541610:0.919906:0.525854:0.523636:0.525854:0.006042:0.012508:0.013143:0.006523:0.011699:0.005707:0.012508:0.007466:0.011276:0.003848:0.011738:0.011276:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.011276:0.015990:0.003848:0.006523:0.011738:0.011276:0.003848:0.013143:0.013123:0.012604:0.005792:0.013143:0.006523:0.012604:0.005792:0.010314:0.005330
findings,  including  genetics  in  trying  to :@0.523636:0.558054:0.919877:0.558054:0.919877:0.542298:0.523636:0.542298:0.004686:0.004686:0.011738:0.013181:0.003848:0.011738:0.012950:0.007466:0.005330:0.005330:0.007491:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005330:0.007495:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.007466:0.005330:0.007491:0.003848:0.011738:0.005330:0.007499:0.006523:0.005792:0.010314:0.003848:0.011738:0.012950:0.005330:0.007491:0.006523:0.012604:0.005330
outline  biologically homogeneous  enti-:@0.523636:0.574498:0.914540:0.574498:0.914540:0.558742:0.523636:0.558742:0.012604:0.011699:0.006523:0.003848:0.003848:0.011738:0.012508:0.005330:0.009415:0.013123:0.003848:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.003848:0.010314:0.014759:0.011738:0.012604:0.018049:0.012604:0.012950:0.012490:0.011738:0.012508:0.012604:0.011699:0.007466:0.005330:0.009415:0.012508:0.011738:0.006523:0.003848:0.006388
ties that have therapeutic and prognostic :@0.523636:0.590942:0.919906:0.590942:0.919906:0.575186:0.523636:0.575186:0.006523:0.003848:0.012508:0.007466:0.005542:0.006523:0.011738:0.013143:0.006523:0.005528:0.011738:0.013143:0.010660:0.012508:0.005542:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.012508:0.011699:0.006523:0.003848:0.012450:0.005526:0.013143:0.011738:0.013181:0.005542:0.013123:0.005717:0.012604:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.005330
relevance.  :@0.523636:0.607386:0.635586:0.607378:0.635586:0.591622:0.523636:0.591630:0.005713:0.012508:0.003848:0.012508:0.010660:0.013143:0.011738:0.012450:0.012508:0.005330:0.006215:-0.036251
3:@0.624038:0.601759:0.630253:0.601759:0.630253:0.592573:0.624038:0.592573:0.006215
Examination of the peripheral blood :@0.541817:0.623822:0.919873:0.623822:0.919873:0.608066:0.541817:0.608066:0.010122:0.009044:0.012950:0.017857:0.003656:0.011545:0.012950:0.006331:0.003656:0.012411:0.011545:0.016029:0.012411:0.005850:0.016029:0.006331:0.011545:0.012315:0.016029:0.012931:0.012315:0.005600:0.003656:0.012931:0.011545:0.012315:0.005600:0.012950:0.003656:0.016029:0.012931:0.003656:0.012411:0.012411:0.013181:0.005330
smear and of the bone marrow (biopsy) :@0.523633:0.640265:0.919909:0.640265:0.919909:0.624510:0.523633:0.624510:0.007274:0.017857:0.012315:0.012950:0.005600:0.009390:0.012950:0.011545:0.012989:0.009390:0.012411:0.005850:0.009390:0.006331:0.011545:0.012315:0.009390:0.012931:0.012411:0.011545:0.012315:0.009390:0.017857:0.012950:0.005600:0.005519:0.012411:0.015798:0.009390:0.006908:0.012931:0.003656:0.012411:0.012931:0.007274:0.010122:0.007102:0.005330
will usually show features of anaemia and :@0.523633:0.656709:0.919861:0.656709:0.919861:0.640953:0.523633:0.640953:0.015798:0.003656:0.003656:0.003656:0.007033:0.011507:0.007274:0.011507:0.012950:0.003656:0.003656:0.010122:0.007033:0.007274:0.011545:0.012411:0.015798:0.007033:0.005850:0.012315:0.012950:0.006331:0.011507:0.005521:0.012315:0.007274:0.007043:0.012411:0.005850:0.007033:0.012950:0.011545:0.012950:0.012315:0.017857:0.003656:0.012950:0.007033:0.012950:0.011545:0.013181:0.005330
thrombocytopaenia with variable morpho-:@0.523633:0.673153:0.914560:0.673153:0.914560:0.657397:0.523633:0.657397:0.006331:0.011545:0.005521:0.012411:0.017857:0.012931:0.012411:0.012257:0.010122:0.006331:0.012411:0.012931:0.012950:0.012315:0.011545:0.003656:0.012950:0.004483:0.015798:0.003656:0.006331:0.011545:0.004483:0.010468:0.012950:0.005600:0.003656:0.012950:0.012931:0.003656:0.012315:0.004483:0.017857:0.012411:0.005600:0.012931:0.011545:0.012411:0.006388
logical abnormalities of the leukocytes and :@0.523633:0.689597:0.919884:0.689597:0.919884:0.673841:0.523633:0.673841:0.003656:0.012411:0.012758:0.003656:0.012257:0.012950:0.003656:0.004426:0.012950:0.012931:0.011545:0.012411:0.006131:0.017857:0.012950:0.003656:0.003656:0.006331:0.003656:0.012315:0.007274:0.004426:0.012411:0.005850:0.004426:0.006331:0.011545:0.012315:0.004426:0.003656:0.012315:0.011507:0.009467:0.012411:0.012257:0.010122:0.006331:0.012315:0.007274:0.004426:0.012950:0.011545:0.013181:0.005330
the presence of circulating malignant cells. :@0.523633:0.706041:0.919888:0.706041:0.919888:0.690285:0.523633:0.690285:0.006331:0.011545:0.012315:0.004445:0.012931:0.005521:0.012315:0.007274:0.012315:0.011545:0.012257:0.012315:0.004445:0.012411:0.005850:0.004445:0.012257:0.003656:0.005465:0.012257:0.011507:0.003656:0.012950:0.006331:0.003656:0.011545:0.012758:0.004445:0.017857:0.012950:0.003656:0.003656:0.012758:0.011545:0.012950:0.011545:0.006331:0.004445:0.012257:0.012315:0.003656:0.003656:0.007274:0.005328:0.005330
By definition, blasts in the bone marrow :@0.541817:0.722485:0.919877:0.722485:0.919877:0.706729:0.541817:0.706729:0.011045:0.010314:0.006923:0.013181:0.012508:0.004686:0.004686:0.011738:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330:0.006906:0.013123:0.003848:0.013143:0.007466:0.006523:0.007466:0.006929:0.003848:0.011738:0.006918:0.006523:0.011738:0.012508:0.006910:0.013123:0.012604:0.011738:0.012508:0.006910:0.018049:0.013143:0.005792:0.005709:0.012604:0.015990:0.005330
exceed 20% of nucleated cells. In promye-:@0.523633:0.738929:0.914550:0.738929:0.914550:0.723173:0.523633:0.723173:0.012508:0.009236:0.012450:0.012508:0.012508:0.013181:0.004297:0.010660:0.010660:0.014913:0.004310:0.012604:0.006042:0.004297:0.011738:0.011699:0.012450:0.003848:0.012508:0.013143:0.006523:0.012508:0.013181:0.004297:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.004310:0.004349:0.011738:0.004301:0.013123:0.005715:0.012604:0.018049:0.010314:0.012508:0.006388
locytic leukaemia (see Figure 2), patients :@0.523633:0.755372:0.919848:0.755372:0.919848:0.739617:0.523633:0.739617:0.003848:0.012604:0.012450:0.010314:0.006523:0.003848:0.012450:0.007370:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143:0.007370:0.007100:0.007466:0.012508:0.012508:0.007370:0.009333:0.003848:0.012950:0.011699:0.005709:0.012508:0.007370:0.010660:0.007100:0.005330:0.007370:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
often  have active laboratory features of :@0.523633:0.771816:0.919873:0.771816:0.919873:0.756060:0.523633:0.756060:0.012604:0.006042:0.006523:0.012508:0.011738:0.005330:0.003298:0.011738:0.013143:0.010660:0.012508:0.008640:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.008640:0.003848:0.013143:0.013123:0.012604:0.005792:0.013143:0.006523:0.012604:0.005792:0.010314:0.008640:0.006042:0.012508:0.013143:0.006523:0.011699:0.005707:0.012508:0.007466:0.008640:0.012604:0.006042:0.005330
DIC with clinical bleeding or thrombosis.  :@0.523633:0.788260:0.919875:0.788254:0.919875:0.772498:0.523633:0.772504:0.014316:0.004349:0.015644:0.008111:0.015990:0.003848:0.006523:0.011738:0.008105:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.008111:0.013123:0.003848:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.008109:0.012604:0.005792:0.008099:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.007466:0.003848:0.007466:0.005330:0.006234:-0.583633
4:@0.908327:0.782635:0.914542:0.782635:0.914542:0.773449:0.908327:0.773449:0.006215
Cytogenetic  analysis  provides some of :@0.523635:0.804698:0.919877:0.804698:0.919877:0.788942:0.523635:0.788942:0.015644:0.010314:0.006523:0.012604:0.012950:0.012508:0.011738:0.012508:0.006523:0.003848:0.012450:0.005330:0.008145:0.013143:0.011738:0.013143:0.003848:0.010314:0.007466:0.003848:0.007466:0.005330:0.008174:0.013123:0.005715:0.012604:0.010660:0.003848:0.013181:0.012508:0.007466:0.013489:0.007466:0.012604:0.018049:0.012508:0.013489:0.012604:0.006042:0.005330
the strongest prognostic information avail-:@0.523635:0.821142:0.914544:0.821142:0.914544:0.805386:0.523635:0.805386:0.006523:0.011738:0.012508:0.005032:0.007466:0.006523:0.005713:0.012604:0.011738:0.012950:0.012508:0.007466:0.006523:0.005042:0.013123:0.005713:0.012604:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.005030:0.003848:0.011738:0.006042:0.012604:0.006319:0.018049:0.013143:0.006523:0.003848:0.012604:0.011738:0.005042:0.013143:0.010660:0.013143:0.003848:0.003847:0.006388
able, predicting outcome  of  both  remis-:@0.523635:0.837586:0.914543:0.837586:0.914543:0.821830:0.523635:0.821830:0.013143:0.013123:0.003848:0.012508:0.005330:0.008813:0.013123:0.005713:0.012508:0.013181:0.003848:0.012450:0.006523:0.003848:0.011738:0.012950:0.008813:0.012604:0.011699:0.006523:0.012450:0.012604:0.018049:0.012508:0.005330:0.003466:0.012604:0.006042:0.005330:0.003473:0.013123:0.012604:0.006523:0.011738:0.005330:0.003473:0.005713:0.012508:0.018049:0.003848:0.007466:0.006388
sion induction and post-remission therapy. :@0.523635:0.854029:0.919882:0.854029:0.919882:0.838273:0.523635:0.838273:0.007466:0.003848:0.012604:0.011738:0.005446:0.003848:0.011738:0.013181:0.011699:0.012450:0.006523:0.003848:0.012604:0.011738:0.005430:0.013143:0.011738:0.013181:0.005446:0.013123:0.012604:0.007466:0.006523:0.006388:0.005711:0.012508:0.018049:0.003848:0.007466:0.007466:0.003848:0.012604:0.011738:0.005434:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
Based on  the  karyotype outcome,  three :@0.523635:0.870473:0.919880:0.870473:0.919880:0.854717:0.523635:0.854717:0.011045:0.013143:0.007466:0.012508:0.013181:0.008755:0.012604:0.011738:0.005330:0.003414:0.006523:0.011738:0.012508:0.005330:0.003414:0.009660:0.013143:0.005792:0.010314:0.012604:0.006523:0.010314:0.013123:0.012508:0.008755:0.012604:0.011699:0.006523:0.012450:0.012604:0.018049:0.012508:0.005330:0.005330:0.003404:0.006523:0.011738:0.005707:0.012508:0.012508:0.005330
prognostic groups are described with five-:@0.523635:0.886917:0.914546:0.886917:0.914546:0.871161:0.523635:0.871161:0.013123:0.005715:0.012604:0.012950:0.011738:0.012604:0.007466:0.006523:0.003848:0.012450:0.005169:0.012950:0.005711:0.012604:0.011699:0.013123:0.007466:0.005184:0.013143:0.005715:0.012508:0.005178:0.013181:0.012508:0.007466:0.012450:0.005792:0.003848:0.013123:0.012508:0.013181:0.005178:0.015990:0.003848:0.006523:0.011738:0.005178:0.004686:0.004686:0.010660:0.012508:0.006388
year  survival of  55-60% in the  favourable :@0.523635:0.903361:0.919882:0.903361:0.919882:0.887605:0.523635:0.887605:0.010314:0.012508:0.013143:0.005792:0.005330:0.003086:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.008428:0.012604:0.006042:0.005330:0.003088:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.008428:0.003848:0.011738:0.008428:0.006523:0.011738:0.012508:0.005330:0.003088:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330
group, 10-15% in the unfavourable group, :@0.523635:0.919805:0.919882:0.919805:0.919882:0.904049:0.523635:0.904049:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.006352:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.006369:0.003848:0.011738:0.006358:0.006523:0.011738:0.012508:0.006350:0.011699:0.011738:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.006360:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.005330
and 35-40%  in the intermediate group. :@0.523635:0.936249:0.919873:0.936249:0.919873:0.920493:0.523635:0.920493:0.013143:0.011738:0.013181:0.012084:0.010660:0.010660:0.006388:0.010660:0.010660:0.014913:0.005330:0.006769:0.003848:0.011738:0.012084:0.006523:0.011738:0.012508:0.012084:0.003848:0.011738:0.006523:0.012508:0.006319:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.012084:0.012950:0.005709:0.012604:0.011699:0.013123:0.005330:0.005330